Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

In8Bio Inc (NQ: INAB )

0.4750 +0.0050 (+1.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 622,805
Open 0.4750
Bid (Size) 0.4000 (3)
Ask (Size) 0.4235 (50)
Prev. Close 0.4700
Today's Range 0.4750 - 0.4750
52wk Range 0.2170 - 2.480
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-64.02%
-64.02%
1 Month
+54.27%
+54.27%
3 Month
-45.56%
-45.56%
6 Month
-52.50%
-52.50%
1 Year
-48.92%
-48.92%

More News

Read More
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
INAB Stock Earnings: IN8bio Misses EPS for Q2 2024
Via InvestorPlace
INAB Stock Earnings: IN8bio Misses EPS for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
INAB Stock Earnings: IN8bio Misses EPS for Q4 2023
Via InvestorPlace
Gold Gains 1%; US Consumer Sentiment Falls In June
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
From IN8bio, Inc
Via GlobeNewswire
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
From IN8bio, Inc
Via GlobeNewswire
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
From IN8bio, Inc
Via GlobeNewswire
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
From IN8bio, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Kill Leukemia Cells While Preserving Healthy Tissues: Nano-Cap Cancer Focused Firm IN8bio's Preclinical Candidate Shows Potential
Via Benzinga
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
From IN8bio, Inc
Via GlobeNewswire
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
From IN8bio, Inc
Via GlobeNewswire
IN8bio to Present at Upcoming Investor Conferences
From IN8bio, Inc.
Via Business Wire
IN8bio’s Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data
Via News Direct
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.